Literature DB >> 15328148

Moxifloxacin treatment of tuberculosis.

Roland Gosling, Stephen Gillespie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15328148      PMCID： PMC514750          DOI： 10.1128/AAC.48.9.3642-3643.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  A multicentre study of the early bactericidal activity of anti-tuberculosis drugs.

Authors:  F A Sirgel; P R Donald; J Odhiambo; W Githui; K C Umapathy; C N Paramasivan; C M Tam; K M Kam; C W Lam; K M Sole; D A Mitchison
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

2.  A reiterative method for calculating the early bactericidal activity of antituberculosis drugs.

Authors:  Stephen H Gillespie; Roland D Gosling; Bambos M Charalambous
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group.

Authors:  R Hafner; J A Cohn; D J Wright; N E Dunlap; M J Egorin; M E Enama; K Muth; C A Peloquin; N Mor; L B Heifets
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

4.  Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.

Authors:  E Miyazaki; M Miyazaki; J M Chen; R E Chaisson; W R Bishai
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

Authors:  A Jindani; V R Aber; E A Edwards; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1980-06

6.  The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.

Authors:  Roly D Gosling; Leonard O Uiso; Noel E Sam; Emily Bongard; Esther G Kanduma; Mramba Nyindo; Richard W Morris; Stephen H Gillespie
Journal:  Am J Respir Crit Care Med       Date:  2003-08-13       Impact factor: 21.405

7.  A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs.

Authors:  Roly D Gosling; Leonid Heifets; Stephen H Gillespie
Journal:  J Antimicrob Chemother       Date:  2003-07-29       Impact factor: 5.790

8.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

Authors:  Mathias W R Pletz; Andres De Roux; Andreas Roth; Karl-Heinz Neumann; Harald Mauch; Hartmut Lode
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
  9 in total
  2 in total

Review 1.  New drugs and regimens for treatment of TB.

Authors:  Eric Leibert; William N Rom
Journal:  Expert Rev Anti Infect Ther       Date:  2010-07       Impact factor: 5.091

2.  Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.

Authors:  Dorothee Heemskerk; Jeremy Day; Tran Thi Hong Chau; Nguyen Huy Dung; Nguyen Thi Bich Yen; Nguyen Duc Bang; Laura Merson; Piero Olliaro; Thomas Pouplin; Maxine Caws; Marcel Wolbers; Jeremy Farrar
Journal:  Trials       Date:  2011-02-02       Impact factor: 2.279
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.